Cargando…
Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance
BACKGROUND: Although significant advances have been made recently to characterize the biology of pancreatic ductal adenocarcinoma (PDAC), more efforts are needed to improve our understanding and to face challenges related to the aggressiveness, high mortality rate and chemoresistance of this disease...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054161/ https://www.ncbi.nlm.nih.gov/pubmed/33862584 http://dx.doi.org/10.1016/j.ebiom.2021.103332 |